IgA Nephropathy – Current Treatment – Detailed, Expanded Analysis – Treatment Algorithms – Claims Data Analysis (US)
Immunoglobulin A nephropathy (IgAN or IgA nephropathy), also known as Berger’s disease, is a rare autoimmune condition that damages the glomeruli inside the kidneys. Initial treatment of IgAN predominantly comprises RAAS inhibitors, SGLT-2 inhibitors, immunosuppressants, and/or diuretics. The FDA’s acceptance of a surrogate clinical trial endpoint—reduction in proteinuria—has enabled the accelerated approval of novel IgAN therapies and the potential for the rapid evolution of the therapeutic landscape. Under this scheme, the FDA approved Calliditas Therapeutics’ Tarpeyo (delayed-release budesonide; now fully approved) and Travere Therapeutics’ Filspari (sparsentan). This report closely examines how the key established and newly launched immunosuppressive and non-immunosuppressive therapies are being used to treat newly diagnosed and recently treated IgAN patients.
Questions answered
- How have Tarpeyo and Filspari been integrated into the treatment algorithm, and in what line of therapy are they usually prescribed to new patients?
- What shares do key therapies and brands garner by line of therapy in newly diagnosed IgAN patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IgAN patients?
- What percentage of IgAN patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What percentage of IgAN patients are treated with monotherapy vs. combination therapy?
- What proportion of patients add Farxiga (dapagliflozin) to their ongoing RAAS inhibitor therapy? What proportion of patients switch to Tarpeyo?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Key companies: Calliditas Therapeutics, Travere Therapeutics, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson
Key drugs: RAAS inhibitors, corticosteroids, Tarpeyo (budesonide delayed-release), Filspari (sparsentan), SGLT-2 inhibitors (Jardiance, Farxiga, Invokana)
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Archita Kukreja, M.B.A., M.S., Lead Healthcare Research & Data Analyst, Cardiovascular, Metabolic, Renal, and Hematologic Disorders. Archita has authored reports on hematological indications like beta thalassemia and sickle cell disease, infectious diseases, and several niche and rare indications. Prior to joining Clarivate, she was a Manager at Sanofi. She has worked on diverse custom and syndicated research project types in several therapeutic areas and has experience in sales- and epidemiology-based forecasting, demand forecasting, commercial opportunity assessments, and market intelligence. She holds double master’s degrees in business administration (M.B.A) and in science (M.S.) with specialization in Biotechnology from Amity University, Noida, India, and Jamia Millia Islamia University, Delhi, India, respectively.